Clinical Trials Expand Patients' Treatment Options
For health conditions with no cure, effective treatments are the next best option. However, in order to make medical ...
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...
Hosted on MSN5d
Torch Gala aims to raise $800,000 for Crohn's and Colitis Foundation
The Crohn’s and Colitis Foundation’s 34th annual Torch Gala is set to take place on Saturday, Feb. 8 in Atlanta, with three ...
Spyre Therapeutics, Inc.: Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...
FDA Approves Lilly's Omvoh® (Mirikizumab-Mrkz) For Crohn's Disease, Expanding Its Use To The Second Major Type Of Inflammatory Bowel Disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic respons ...
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio
First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in ...
PharmiWeb2d
Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...
To Iowans like Brian Thompson, reputation matters; UnitedHealth must improve its | Opinion
The slain CEO of the insurer had a vision for positive change; his company should embrace new consumer remedies, writes .
Armed robbery in Revesby23h
Wearables Predict Inflammatory Bowel Disease Flare-ups
Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in inflammatory bowel disease ...
Jane Street Group LLC Increases Position in Immunic, Inc. (NASDAQ:IMUX)
Jane Street Group LLC lifted its position in shares of Immunic, Inc. (NASDAQ:IMUX – Free Report) by 121.4% in the 3rd quarter ...
Short Interest in ABIVAX Société Anonyme (NASDAQ:ABVX) Rises By 47.9%
ABIVAX Société Anonyme (NASDAQ:ABVX – Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 853,600 ...